Wound Management Sells Non-Core Subsidiary; Intends to Focus on CellerateRX and Medical Device Business
Written on Feb 7, 2012
Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK), an emerging innovator in advanced wound care solutions, has sold its wholly-owned subsidiary, Secure eHealth, LLC (“Secure eHealth”), to two entities that previously financed the acquisition of Secure eHealth by WNDM in January 2010. In...
TONIX Pharmaceuticals Completes $4.3 Private Placement Funding
Written on Feb 7, 2012
TONIX Pharmaceuticals, a New York-based specialty pharmaceutical company (TNXP.OB), focused on developing therapies to treat central nervous system conditions such as fibromyalgia (FM) and post-traumatic stress disorder (PTSD), just completed a $4.3 private placement offering to institutional and...
This Week In Diagnostics
Written on Feb 6, 2012
IPSOGEN acquires rights for new cancer biomarkers
IPSOGEN SA (Alternext: ALIPS), a majority-owned subsidiary of QIAGEN N.V. (Nasdaq: QGEN), has reported that it has acquired the worldwide exclusive rights to testing for mutations of the IDH1 and IDH2 genes for diagnostic purposes from Baltimore,...
BREAKING NEWS: Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer
Written on Jan 26, 2012
Click below to hear live audio interview with Thomas Moore, CEO.
PRINCETON, N.J., Jan. 25 — Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, reported preliminary...
S.E.A. Medical Secures $3 Million in Series B Financing from JK&B Capital
Written on Jan 26, 2012
SANTA CLARA, Calif.–S.E.A. Medical Systems Inc., a healthtech company focused on safety and management of IV medicine, today announced that it closed a $3 million Series B investment with Chicago-based venture capital firm JK&B Capital, which specializes in investments in Information Technologies,...
Provectus Receives Guidance From FDA On Pathway to Approval for Phase 3 Trial of PV-10 For Metastatic Melanoma
Written on Jan 25, 2012
KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received guidance from the U.S. Food and Drug Administration (“FDA”) to submit its Phase 3 protocol for...
